Header

UZH-Logo

Maintenance Infos

Cost-Effectiveness of Losartan Versus Atenolol in Treating Hypertension - An Analysis of the LIFE Study from a Swiss Perspective


Szucs, Thomas D; Burnier, Michel; Erne, Paul (2004). Cost-Effectiveness of Losartan Versus Atenolol in Treating Hypertension - An Analysis of the LIFE Study from a Swiss Perspective. Cardiovascular Drugs and Therapy, 18(5):391-397.

Abstract

Aims: To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system. Methods and results: The cost-effectiveness of losartan versus atenolol in the treatment of hypertension was analyzed by applying the results of the LIFE study to the Swiss healthcare system using a decision analysis framework. The cost-effectiveness shows the losartan cohort to provide an additional life expectancy of 0.05 years per patient compared to the atenolol cohort, over a mean follow-up period of 4.8 years. Losartan therapy in hypertensive patients produced net cost savings of CHF 24 per patient and per 4.8 years compared to atenolol from the perspective of the Swiss health care system. This result was robust after varying costs of medication, stroke, myocardial infarction and life expectancy. Conclusion: The use of a losartan-based regimen in hypertensive patients with left ventricular hypertrophy in Switzerland is net cost-saving compared with a atenolol-based regimen

Abstract

Aims: To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system. Methods and results: The cost-effectiveness of losartan versus atenolol in the treatment of hypertension was analyzed by applying the results of the LIFE study to the Swiss healthcare system using a decision analysis framework. The cost-effectiveness shows the losartan cohort to provide an additional life expectancy of 0.05 years per patient compared to the atenolol cohort, over a mean follow-up period of 4.8 years. Losartan therapy in hypertensive patients produced net cost savings of CHF 24 per patient and per 4.8 years compared to atenolol from the perspective of the Swiss health care system. This result was robust after varying costs of medication, stroke, myocardial infarction and life expectancy. Conclusion: The use of a losartan-based regimen in hypertensive patients with left ventricular hypertrophy in Switzerland is net cost-saving compared with a atenolol-based regimen

Statistics

Citations

Dimensions.ai Metrics
9 citations in Web of Science®
12 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

21 downloads since deposited on 19 Oct 2018
21 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 September 2004
Deposited On:19 Oct 2018 12:43
Last Modified:18 Nov 2018 13:20
Publisher:Springer
ISSN:0920-3206
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1007/s10557-005-5064-x
Related URLs:https://www.swissbib.ch/Search/Results?lookfor=nationallicencespringer101007s105570055064x (Library Catalogue)

Download

Download PDF  'Cost-Effectiveness of Losartan Versus Atenolol in Treating Hypertension - An Analysis of the LIFE Study from a Swiss Perspective'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 280kB
View at publisher